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Acute stimulation of glucose influx uponmitoenergetic dysfunction
requires LKB1, AMPK, Sirt2 and mTOR–RAPTOR
Dania C. Liemburg-Apers1,2,3, Jori A. L. Wagenaars1,2,3, Jan A. M. Smeitink2,3, Peter H. G. M. Willems1,2,3 and
Werner J. H. Koopman1,2,3,*
ABSTRACT
Mitochondria play a central role in cellular energy production, and
their dysfunction can trigger a compensatory increase in glycolytic
flux to sustain cellular ATP levels. Here, we studied the mechanism of
this homeostatic phenomenon in C2C12 myoblasts. Acute (30 min)
mitoenergetic dysfunction induced by the mitochondrial inhibitors
piericidin A and antimycin A stimulated Glut1-mediated glucose
uptake without altering Glut1 (also known as SLC2A1) mRNA or
plasma membrane levels. The serine/threonine liver kinase B1
(LKB1; also known as STK11) and AMP-activated protein kinase
(AMPK) played a central role in this stimulation. In contrast, ataxia-
telangiectasia mutated (ATM; a potential AMPK kinase) and
hydroethidium (HEt)-oxidizing reactive oxygen species (ROS;
increased in piericidin-A- and antimycin-A-treated cells) appeared
not to be involved in the stimulation of glucose uptake. Treatment with
mitochondrial inhibitors increased NAD+ and NADH levels
(associated with a lower NAD+:NADH ratio) but did not affect the
level of Glut1 acetylation. Stimulation of glucose uptake was greatly
reduced by chemical inhibition of Sirt2 or mTOR–RAPTOR. We
propose that mitochondrial dysfunction triggers LKB1-mediated
AMPK activation, which stimulates Sirt2 phosphorylation, leading to
activation of mTOR–RAPTOR and Glut1-mediated glucose uptake.
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INTRODUCTION
Glucose is one of the main substrates for ATP production and enters
the cell through a family of facilitative glucose transporters (Gluts)
(Zhao and Keating, 2007). Glut-mediated glucose transport depends
on the difference between the extracellular ([GLC]ext) and cytosolic
glucose ([GLC]c) concentration. In the cytosol, glucose is
phosphorylated by hexokinase to form glucose-6-phosphate
(G6P). This process co-determines the magnitude of the glucose
gradient across the plasma membrane and, thereby, the rate of Glut-
mediated glucose influx (Barros et al., 2007). Glucose is converted
by the glycolysis pathway into pyruvate, which generates ATP.
Pyruvate can be taken up by the mitochondria, where it is converted
into acetyl coenzyme A. Subsequent oxidation through the
tricarboxylic acid (TCA) cycle yields NADH and FADH2, which
are oxidized by complex I and complex II, respectively, of the
mitochondrial oxidative phosphorylation (OXPHOS) system. The
OXPHOS system uses the energy released through electron
transport to generate ATP through chemiosmotic coupling
(Mitchell, 1961). Each OXPHOS complex comprises multiple
subunits and requires the assistance of proteinaceous assembly
factors to catalyze its biogenesis (Acin-Perez and Enriquez, 2014;
Nouws et al., 2012). Mutations in structural subunits or assembly
chaperones induce mitochondrial disease in humans (Koene et al.,
2012; Loeffen et al., 2000; van den Heuvel and Smeitink, 2001).
Inherited complex-I deficiencies are the most common OXPHOS
disorders (Bénit et al., 2009), whereas myopathy has been linked to
an off-target effect of statins on complex III (Schirris et al., 2015).
Moreover, empirical evidence suggests that inhibition of complex I
mediates the action of the antidiabetic drug metformin and is
relevant in cancer treatment (Chen et al., 2007; Schöckel et al.,
2015; Vatrinet et al., 2015; Zhang et al., 2014). In addition to
genetic errors of energy metabolism, mitoenergetic dysfunction has
also been linked to diabetes, obesity and neurodegenerative
disorders (Carelli et al., 2009; Chandra and Singh, 2011; Correia
et al., 2012; Costa and Scorrano, 2012; Finsterer and Mahjoub,
2013; Koopman et al., 2013; Martin, 2011; Patti and Corvera, 2010;
Ritov et al., 2010; Swerdlow, 2012).
To cope with mitoenergetic dysfunction and prevent energy
crisis, cells can increase their glycolytic rate and thereby ATP
production (Elstrom et al., 2004; Epstein et al., 2014; Liemburg-
Apers et al., 2015a). For instance, an increased glycolytic rate has
been observed in fibroblasts from individuals with myoclonic
epilepsy and ragged-red fibers (MERRF) syndrome (Wu and Wei,
2012) and in cells chronically treated with the complex-I inhibitor
rotenone (Distelmaier et al., 2015). Also, silencing of the complex-I
gene NDUFS3 triggers a glycolytic switch (Suhane et al., 2013). To
increase the glycolytic rate, cells can stimulate Glut-mediated
glucose uptake (Barros et al., 2007). The Glut family comprises 14
members, among which Glut1 (also known as SLC2A1) is the best-
studied and most abundant isoform in proliferating cells (Mann
et al., 2003). Glut1 is an integral membrane glycoprotein
comprising 12 membrane-spanning α-helices (Mueckler et al.,
1985). Mechanistically, Glut1 transport capacity can be stimulated
by (i) increasing the translocation of Glut1-containing vesicles from
the cytosol to the plasma membrane (Cura and Carruthers, 2012;
Jing et al., 2008; Wheeler, 1988) or (ii) stimulating the activity of
Glut1 transporters that are already present at the plasma membrane
(Abbud et al., 2000; Barnes et al., 2002; Hamrahian et al., 1999;
Loaiza et al., 2003; Mercado et al., 1989; Shetty et al., 1993; Shi
et al., 1995). In a recent study (Liemburg-Apers et al., 2015a), we
have demonstrated that acute (30 min) inhibition of complex I (with
piericidin A) or of complex III (with antimycin A) increases glucose
uptake and consumption in C2C12 myoblasts. This suggests thatReceived 27 June 2016; Accepted 24 October 2016
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mitoenergetic dysfunction evokes a rapid compensatory increase in
steady-state glucose uptake and consumption to prevent energy
crisis in cells that are compromised in mitochondrial ATP
generation. Here, we provide evidence suggesting that this
compensatory process involves the stimulation of Glut1 activity
through a mechanism requiring LKB1 (also known as STK11),
AMPK, Sirt2 and the mTOR–RAPTOR complex.
RESULTS
Measurement of glucose uptake in C2C12 myoblasts during
acute OXPHOS inhibition
To measure glucose levels, C2C12 myoblasts were transfected with
the glucose sensor FLII12Pglu-700μδ6 (FLII) (Takanaga et al.,
2008) and imaged using epifluorescence microscopy. FLII
comprises a glucose-binding domain attached to CFP and the
YFP-variant citrine. Glucose binding and unbinding induces
conformational changes that affect the efficiency of fluorescence
resonance energy transfer (FRET) from CFP to citrine. Previously,
we have calibrated the citrineFRET:CFP emission ratio signal in
C2C12 cells, allowing quantification of the free cytosolic glucose
concentration ([GLC]c) (Liemburg-Apers et al., 2015a). To study
the effects of mitochondrial dysfunction, we used our recently
described incubation protocol (Liemburg-Apers et al., 2015a). First,
cells were pretreated (30 min) with vehicle (0.01% ethanol), the
complex-I inhibitor piericidin A (100 nM), or the complex-III
inhibitor antimycin A (20 nM). Mitochondrial inhibitors were used
at concentrations that fully blocked mitochondrial O2 consumption
(Liemburg-Apers et al., 2015a). Next, cytosolic glucose was
depleted by placing the cells in a glucose-free medium for
18 min. During the last 15 min of this incubation, glucose
consumption was blocked by adding the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) inhibitor iodoacetic acid
(IAA; 500 µM). Importantly, under these conditions glucose
consumption was completely blocked (Liemburg-Apers et al.,
2015a). This allowed quantification of the maximum rate of [GLC]c
increase (Fig. 1A; lines), which is a measure of the maximal rate of
glucose uptake, upon extracellular addition of 2 mM of glucose
(Liemburg-Apers et al., 2015a).
Acute OXPHOS inhibition stimulates Glut1-mediated
glucose uptake without increasing Glut1 levels at the
plasma membrane
Piericidin A and antimycin A treatment increased the rate of glucose
uptake (Fig. 1A,B). Quantitative (Q)PCR analysis revealed that
Glut1 was expressed, whereas mRNAs for Glut2, Glut3 and Glut4
(also known as SLC2A2, SLC2A3 and SLC2A4, respectively) were
not detected (Fig. 1C). Glut1 mRNA levels were unaltered by
inhibitor treatment (piericidin A and antimycin A), whereas
exposure to CoCl2 (250 µM, 4.5 h), a treatment previously
demonstrated to increase Glut1 expression (Barnes et al., 2002;
Behrooz and Ismail-Beigi, 1997), increased these levels without
inducing expression of the other Glut isoforms (Fig. 1C). In
principle, piericidin A and antimycin A treatment could increase
glucose uptake by stimulating the translocation of Glut1 from the
cytosol to the plasma membrane (Barnes et al., 2002). Also, IAA
treatment might affect Glut1 levels at the plasma membrane given
the proposed involvement of GAPDH in vesicular transport (Zala
et al., 2013). However, immunocytochemical analysis of Glut1
localization did not reveal obvious changes in cytosolic versus
plasma membrane levels (Fig. 1D). Similarly, quantification of
Glut1 levels at the plasma membrane using a biotinylation assay of
cell surface Glut1 and cell-impermeable biotin (Barnes et al., 2002;
Cura and Carruthers, 2012) revealed no alteration in the levels of
biotinylated Glut1 (Fig. 1E). Taken together, these results suggest
that the acute stimulation of glucose uptake by piericidin A and
antimycin A is mediated by Glut1 but is not due to increased Glut1
levels at the plasma membrane.
Stimulation of Glut1-mediated glucose uptake by acute
OXPHOS requires AMPK activation
During metabolic dysfunction, increased Glut1-mediated glucose
uptake has been linked to phosphorylation of residue Thr172
(activation) of the energy stress sensor AMP-activated protein
kinase (AMPK) (Abbud et al., 2000; Barnes et al., 2002; Cura and
Carruthers, 2012; Hardie, 2015; Jing et al., 2008; Wu et al., 2013).
Piericidin A and antimycin A treatment increased the levels of
Thr172-phosphorylated AMPK (pAMPK; Fig. 2A). Also, the
(inhibitory) phosphorylation of residue Ser79 of the pAMPK
effector acetyl-CoA carboxylase (yielding pACC) appeared to be
increased in piericidin-A- and antimycin-A-treated cells (Fig. 2B).
The latter suggests that the increased level of pAMPK is paralleled
by increased AMPK activity. Exogenous AMPK activation by 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR; 500 µM,
30 min) increased both pAMPK levels (Fig. 2C) and glucose uptake
(Fig. 2D), although to a lesser extent than that with piericidin
A. AICAR did not display an additive effect in combination with
piericidin A, suggesting that AICAR and piericidin A stimulate
glucose uptake through the same mechanism. To determine whether
AMPK activity was required for piericidin-A- and antimycin-A-
induced stimulation of glucose uptake, cells were pretreated with the
cell-permeable AMPK inhibitor Compound C (20 µM, 2 h). This
compound binds to the AMPK α2 catalytic subunit (encoded by
PRKAA2) in a pocket that partially overlaps with the putative ATP-
binding site (Handa et al., 2011). Pretreatment with Compound C
reduced the piericidin-A- and antimycin-A-stimulated increase in
glucose uptake (Fig. 2E) and somewhat lowered antimycin-A-
stimulated pACC formation (Fig. 2F). These findings suggest that
AMPK activity is required for inhibitor-induced stimulation of
Glut1-mediated glucose uptake. However, Compound C can also
display off-target effects (Bain et al., 2007; Vogt et al., 2011).
Therefore, we next used a knockdown strategy with small
interfering (si)RNAs co-targeting the α1 (PRKAA1) and α2
catalytic subunits of AMPK (Cura and Carruthers, 2012). As
intended, AMPK knockdown lowered the levels of pAMPK in
vehicle-, piericidin-A- and antimycin-A-treated cells (Fig. 2G). This
was paralleled by a reduction in inhibitor-stimulated glucose uptake
(Fig. 2H). The above findings suggest that acute OXPHOS
inhibition activates glucose uptake through a mechanism
involving activation of AMPK through phosphorylation at Thr172.
Stimulation of Glut1-mediated glucose uptake by acute
OXPHOS inhibition requires LKB1
In mammals, AMPK Thr172 phosphorylation is primarily mediated
by two upstream kinases (Hardie et al., 2012): (i) a complex
comprising LKB1, STRAD (STRADA) andMO25 (CAB39), which
was originally identified as a tumor suppressor and (ii) Ca2
+/calmodulin-activated protein kinase kinase β (CaMKK1 or
CaMKK2). Mechanistically, LKB1–STRAD–MO25 induces a high
basal level of Thr172 phosphorylation that is modulated by the
binding of AMP to the AMPK γ-subunit (Xie et al., 2006). The latter
stimulates AMPKphosphorylation and inhibits its dephosphorylation
(Davies et al., 1995; Hawley et al., 1995). LKB1 is activated by
phosphorylation of Ser431 (yielding pLKB1) during a variety of
conditions (Gan and Li, 2014). Piericidin A and antimycin A
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treatment apparently increased the level of pLKB1 (Fig. 3A).
Knockdown of LKB1 reduced the inhibitor-induced stimulation of
AMPK Thr172 phosphorylation (Fig. 3B). Surprisingly, LKB1
knockdown did not affect glucose uptake in vehicle- or piericidin-A-
treated cells but reduced this parameter in antimycin-A-treated cells
(Fig. 3C). These results suggest that although LKB1 is involved in
mediating the stimulation of glucose uptake in antimycin-A-inhibited
cells, additional modes of regulation are involved in piericidin-A-
induced stimulation of glucose uptake. In this sense, the ataxia
telangiectasia mutated (ATM) protein has been demonstrated to
activate AMPK through an LKB1-independent mechanism in
AICAR-treated cells (Sun et al., 2007). However, pretreatment with
the ATM inhibitor KU55933 (1 µM, 1 h) (Hickson et al., 2004) did
not significantly reduce the piericidin-A-induced increase in glucose
uptake (Fig. 3D), suggesting that ATM is not a primary regulator of
glucose uptake in our model.
Stimulation of Glut1-mediated glucose uptake by acute
OXPHOS inhibition is not prevented by antioxidants
Both inhibitor-induced and inherited mitochondrial dysfunction are
generally characterized by increased ROS levels (Forkink et al.,
2015a; Koopman et al., 2013, 2012; Willems et al., 2015; Zorov
et al., 2014). These ROS might be involved in the regulation of
cellular glucose metabolism (Liemburg-Apers et al., 2015b).
Although still controversial, it has been proposed that ROS and/or
changes in redox state might also activate AMPK (Han et al., 2010;
Jensen et al., 2008; Mungai et al., 2011; Wu and Wei, 2012;
Zmijewski et al., 2010). Using a previously described strategy
(Forkink et al., 2015b; Grefte et al., 2015), we quantified the
oxidation of the ROS sensor hydroethidium (HEt; Fig. 4A). This
revealed that antimycin A and piericidin A increased the levels of
HEt-oxidizing ROS (Fig. 4B). Increased piericidin-A-induced HEt
oxidation was unaffected by pretreatment with the antioxidant
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Fig. 1. Acute OXPHOS inhibition stimulates Glut1-mediated glucose uptake without affecting Glut1 levels at the plasma membrane. (A) Myoblasts
expressing the glucose sensor FLII were incubated for 30 min with vehicle (Veh), piericidin A (PA) or antimycin A (AA) and glucose (GLC) uptake was measured
by using fluorescencemicroscopy. Prior to this, myoblasts were incubated for 18 min in the absence of glucose, the last 15 min of which was in the presence of the
glucose-consumption inhibitor IAA. Then, the FLII fluorescence emission ratio (citrineFRET:CFP) wasmeasured during the addition of 2 mM extracellular glucose.
The citrineFRET:CFP was calibrated, allowing calculation of the cytosolic free glucose concentration [GLC]c in mM. The rate of [GLC]c increase (lines) was
quantified and taken as a measure of the rate of glucose uptake. (B) The average rate of glucose uptake in vehicle-, piericidin-A- and antimycin-A-treated cells.
(C) QPCR analysis of Glut1, Glut2, Glut3 and Glut4 expression in cells that had been pretreated with vehicle, piericidin A, antimycin A or CoCl2 (positive control).
Expression levels were normalized to actin expression. (D) Immunocytochemical analysis of Glut1 (green) in cells that had been treated with vehicle (in absence
or presence of IAA), piericidin A or antimycin A. Cells were co-stained with DAPI to visualize nuclei (blue). (E) Upper panel, level of biotinylated Glut1 in vehicle-
(in the absence or presence of IAA), piericidin-A- and antimycin-A-treated cells. Lower panel, mean levels of biotinylated Glut1 (normalized to the vehicle-treated
condition). Statistics: mean±s.e.m. represents seven independent experiments (A,B, >75 cells per condition) and three independent experiments (C,E).
Significant differences with the indicated column conditions (indicated by letters) are as marked; *P<0.05 and ***P<0.001 (Dunn’s post-hoc test).
4413
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 4411-4423 doi:10.1242/jcs.194480
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
Tempol (400 µM, 30 min), but was significantly reduced by the
antioxidant Trolox (30 µM; 30 min; Fig. 4C,D). However, both
antioxidants did not significantly affect the piericidin-A-induced
increase in glucose uptake (Fig. 4E) and pAMPK levels (Fig. 4F).
Taken together, these results suggest that the elevated levels of HEt-
oxidizing ROS in piericidin-A-treated cells are not responsible for
stimulation of the pAMPK-mediated increase in glucose uptake in
cells with inhibited OXPHOS.
Stimulation of Glut1-mediated glucose uptake by acute
OXPHOS inhibition has a maximum level
By combining data obtained in acutely treated cells, it was found
that the pAMPK level and glucose uptake displayed a sigmoidal
relationship (Fig. 5). This supports our above result that pAMPK is
required for acute stimulation of Glut1-mediated glucose uptake and
suggests that the latter has a limited capacity.
Stimulation of Glut1-mediated glucose uptake by acute
OXPHOS inhibition requires Sirt2 activity
Chemical inhibition of complex I and complex III is associated with
increased mitochondrial NADH levels (Forkink et al., 2015a).
Similarly, genetic complex-I deficiency in mouse embryonic
fibroblasts from NDUFS4−/− mice is characterized by lower
cellular levels of NAD+ and increased levels of NADH (leading
to a reduced NAD+:NADH ratio), without alterations in NADP+ and
NADPH levels (Valsecchi et al., 2012). Using a heart-specific
NDUFS4−/− mouse model, further evidence has been provided that
complex-I deficiency is associated with a reduced NAD+:NADH
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Fig. 2. Stimulation of glucose uptake by
acute OXPHOS inhibition involves AMPK.
(A) Western blot analysis of the levels of
AMPK (top panel) and pAMPK (top panel
and bottom bar graph) in vehicle (Veh)-,
piericidin A (PA)- and antimycin A (AA)-
treated cells. Protein levels were normalized
to actin protein levels and those under the
vehicle-treated condition. (B) Western blot
analysis of the levels of pACC in vehicle-,
piericidin-A- and antimycin-A-treated cells.
Protein levels were normalized to actin
protein levels and those under the vehicle-
treated condition. (C) Western blot analysis
of the levels of pAMPK in vehicle-, AICAR-,
piericidin-A- and piericidin-A+AICAR-treated
cells. Protein levels were normalized to actin
protein levels and those under the vehicle-
treated condition. (D) Effect of AICAR,
piericidin A and piericidin-A+AICAR on the
rate of glucose (GLC) uptake. (E) Effect of
pretreatment with the AMPK inhibitor
Compound Con the rate of glucose uptake in
vehicle-, piericidin-A- and antimycin-A-
treated cells. (F) Effect of Compound C
pretreatment on pACC levels in antimycin-A-
treated cells. (G) Western blot analysis of the
effect of scrambled siRNA and siRNA
against AMPK-α1 and -α2 (AMPK KD) on
pAMPK levels in vehicle-, piericidin-A- and
antimycin-A-treated cells. (H) Effect of
scrambled siRNA and AMPK KD on the rate
of glucose uptake in vehicle-, piericidin-A-
and antimycin-A-treated cells. Statistics:
mean±s.e.m. represent three independent
experiments (A–C,H) or four independent
experiments (D,E). For D,E and H, >50 cells
were analyzed per condition. Significant
differences with the indicated columns and
conditions (indicated by letters) are as
marked; *P<0.05, **P<0.01 and ***P<0.001;
Dunn’s post-hoc test (A–E,H) and Bonferroni
post-hoc test (E,H).
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ratio and that this reduction is paralleled by a lower activity of the
NAD+-dependent deacetylase sirtuin 3 (Sirt3) (Karamanlidis et al.,
2013). As a consequence, protein acetylation is increased and heart
failure accelerated. Here, we observed that piericidin A and
antimycin A treatment increased the total cellular level of NADH
(Fig. 6A; open bars), and possibly of NAD+ (Fig. 6B; open bars),
resulting in a lower NAD+:NADH ratio (Fig. 6C; open bars). In
AMPK-knockdown cells, the inhibitor-induced increase in NADH
was fully prevented and NAD+ levels were decreased (Fig. 6A–C;
filled bars). In order to assess a possible role for sirtuin proteins in
our model system, we specifically inhibited sirtuin 2 (i.e. Sirt2),
which displays a cytosolic localization (Poulose and Raju, 2015). In
vehicle-treated cells, inhibition of Sirt2 activity by using the specific
inhibitor AGK2 (5 µM, 2 h) (Outeiro et al., 2007) stimulated
glucose uptake (Fig. 6D). This suggests that Sirt2 activity inhibits
glucose uptake under this condition. Enigmatically, in piericidin-A-
and antimycin-A-treated cells, increased glucose uptake was
reduced upon Sirt2 inhibition, suggesting that Sirt2 activity is
required to allow stimulation of glucose uptake (Fig. 6D). AGK2
treatment did not affect the inhibitor-induced increase in pAMPK
levels, compatible with Sirt2 being a downstream effector of
pAMPK (Fig. 6E). Next, it was assessed whether Sirt2 might
stimulate glucose uptake through deacetylation of Glut1. First, all
proteins with acetylated lysine residues were immunoprecipitated,
and Glut1 levels were analyzed by western blotting. Indeed, Glut1
was detected, but its acetylation status was not significantly affected
by piericidin A or antimycin A treatment (Fig. 6F). To confirm
Glut1 acetylation, Glut1 was immunoprecipitated and acetyl-lysine
was analyzed on a western blot. A band specific for acetyl-lysine
was found to run at the same place on a gel as that for Glut1
(Fig. 6G). Again, the acetylation status of Glut1 was unaffected by
piericidin A or antimycin A treatment (Fig. 6G). The above results
suggest that Sirt2 is involved in piericidin-A- and antimycin-A-
induced stimulation of glucose uptake, but that Glut1 is not a direct
deacetylation target of Sirt2.
Stimulation of Glut1-mediated glucose uptake by acute
OXPHOS inhibition requires the activity of mTOR–RAPTOR
A previous study has suggested that AMPK can phosphorylate Sirt2
at Thr101 and that this phosphorylation is required for the
interaction with the serine/threonine protein kinase Akt (of which
there are three isoforms) (Ramakrishnan et al., 2014). This
interaction between Sirt2 and Akt is required to allow optimal Akt
activation. In this sense, previous evidence has revealed that Akt
inhibitors effectively block the mammalian target of rapamycin
complex 1 (mTORC1; containing mTOR and RAPTOR) and
decrease glucose uptake, glycolytic rate and cell viability (Rashmi
et al., 2014). In agreement with our above results, it has been
concluded previously that mTOR–RAPTOR promotes Glut1
activity but does not regulate Glut1 surface localization (Wieman
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uptake in vehicle- and piericidin-A-treated cells. Statistics: mean±s.e.m. represents three independent experiments (A–C) and four independent experiments (D). For
C,D, >50 cells were analyzed per condition. Significant differences with the indicated columns and conditions (indicated by letters) are asmarked; *P<0.05, **P<0.01
and ***P<0.001; Dunn’s post-hoc test (A–D) and Bonferroni’s post-hoc test (B–D).
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et al., 2007). In order to assess the potential involvement of Akt in
the piericidin-A- and antimycin-A-induced increase in glucose
uptake, we tested the pan-Akt inhibitor SC-66 (Jo et al., 2011).
Pretreatment with SC-66 (10 μg/ml, 1 h) (Rashmi et al., 2014) did
not reduce the stimulation of glucose uptake in inhibitor-treated
cells (data not shown). Assuming that the effect of SC-66 is Akt
specific, this result argues against involvement of Akt in the
stimulation of glucose uptake. Next, to assess the potential
involvement of mTOR–RAPTOR in the piericidin-A- and
antimycin-A-induced increase in glucose uptake, we used the
mTOR inhibitor rapamycin. Pretreatment with rapamycin (25 nM,
24 h) (Wieman et al., 2007) greatly reduced the stimulation of
glucose uptake in inhibitor-treated cells (Fig. 6H), supporting the
hypothesis that mTOR–RAPTOR promotes Glut1 transporter
activity (Wieman et al., 2007). The above results suggest that
mTOR–RAPTOR is involved in piericidin-A- and antimycin-A-
induced stimulation of glucose uptake, potentially through an
Akt-independent mechanism.
DISCUSSION
Increased Glut1-mediated glucose uptake during metabolic stress is
an important cellular adaptation mechanism. Understanding the
latter is of relevance for a broad spectrum of metabolic disorders,
including mitochondrial dysfunction, cancer and diabetes. Here, we
show that 30 min of inhibition of mitochondrial complex I or
complex III increases the rate of glucose uptake without increasing
the abundance of Glut1 at the plasma membrane. This suggests that
Glut1 preexisting at the plasma membrane becomes activated. Our
findings suggest that Glut1 activation is mediated by a signaling
cascade involving LKB1, AMPK, Sirt2 and mTOR–RAPTOR.
Although stimulation of glucose uptake through short-term
inhibition of OXPHOS complexes has been described previously,
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(B). For B–E, >30 cells were analyzed per
condition. Significant differences with the
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*P<0.05, **P<0.01 and ***P<0.001;
Students-t test (B–D), Bonferroni’s post-
hoc test (E,F) and Dunn’s post-hoc test (F).
4416
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 4411-4423 doi:10.1242/jcs.194480
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
its underlying mechanism still remains poorly understood (Barros
et al., 1995; Hamrahian et al., 1999; Jing et al., 2008; Koseoglu and
Beigi, 1999; Liemburg-Apers et al., 2015a; Mercado et al., 1989;
Shetty et al., 1993; Shi et al., 1995). Here, we provide evidence that
mitochondrial inhibition neither increases Glut1 mRNA levels nor
Glut1 abundance at the plasma membrane, which is compatible with
the relatively fast stimulation of glucose uptake. Inhibition of ATM,
a protein that promotes Glut1 plasma membrane localization in
myoblasts (Andrisse et al., 2013), did not diminish the increased rate
of glucose uptake induced by piericidin A. This suggests that Glut1
internalization, as well as the translocation of Glut1-containing
vesicles to the plasma membrane, is unaffected by acute
mitochondrial inhibition. In other cell types, metabolic stress
increases the activity of Glut1 that is already localized at the plasma
membrane (Abbud et al., 2000; Barnes et al., 2002; Koseoglu and
Beigi, 1999; Shetty et al., 1993; Shi et al., 1995). Our previous
results have demonstrated that piericidin A and antimycin A
increase the Vmax of the Glut1-mediated glucose uptake without
affecting the affinity (Km) of this process (Liemburg-Apers et al.,
2015a). Taken together, the above data suggest that inactive Glut1
molecules at the plasma membrane are activated during
mitochondrial inhibition. For instance, ATP allosterically inhibits
Glut1 and therefore Vmax is increased when ATP levels are reduced
(Carruthers and Helgerson, 1989). The latter might occur upon
acute mitochondrial inhibition and trigger a compensatory increase
in glucose uptake. However, Glut1 activity remains increased after
ATP levels return to normal in clone 9 cells with an inhibited
complex I (Mercado et al., 1989). This is compatible with the
normal total cellular ATP levels measured after 24 h in piericidin-A-
and antimycin-A-treated C2C12 cells (Liemburg-Apers et al.,
2015a).
We observed that piericidin A and antimycin A treatment
triggered AMPK activation. In addition, AICAR-induced AMPK
activation was paralleled by an increase in glucose uptake under
vehicle-treated conditions. AICAR did not further increase glucose
uptake in piericidin-A-treated cells, suggesting that AICAR and
piericidin A stimulate this uptake through the same mechanism. The
latter observation is compatible with previous studies showing that
short-term metabolic stress stimulates Glut1-mediated glucose
uptake in an AMPK-dependent manner (Abbud et al., 2000;
Barnes et al., 2002; Jing and Ismail-Beigi, 2007). Importantly, acute
chemical inhibition of AMPK activity or knockdown of its α1 and
α2 subunits partially inhibited the increased glucose uptake that was
induced by mitochondrial inhibition. This partial inhibition might be
due to the fact that AMPK phosphorylation was still higher in
piericidin-A or antimycin-A-treated than in vehicle-treated cells.
Piericidin A and antimycin A treatment slightly increased the levels
of pLKB1; this is compatible with a mechanism in which a high basal
LKB1 activity continuously stimulates Thr172 phosphorylation on
AMPK, which is immediately counterbalanced by
dephosphorylation when AMP is low (Hardie, 2011). Acute
mitochondrial inhibition increases the AMP:ATP ratio (Jing and
Ismail-Beigi, 2007; Mercado et al., 1989; Shetty et al., 1993), and
AMP binding to the AMPK γ-subunit enhances phosphorylation of
the α-subunit by the upstream AMPK kinase LKB1 (Hardie and
Ashford, 2014; Shaw et al., 2004; Woods et al., 2003). In addition,
AMP binding induces a conformational change that inhibits AMPK
dephosphorylation (Davies et al., 1995; Sanders et al., 2007). LKB1
knockdown significantly inhibited piericidin-A- and antimycin-A-
induced AMPK activation but only prevented stimulation of glucose
uptake in antimycin-A-treated cells. This might suggest that
piericidin A activates AMPK through an alternative route when
LKB1 levels are low. Piericidin A treatment increased ROS levels to a
greater extent than antimycin A treatment. It has also been suggested
that increased ROS levels and/or ATM activation can also (in)directly
activate AMPK (Guo et al., 2010; Kurz et al., 2004; Zmijewski et al.,
2010). However, treatment with antioxidants and ATM inhibition
were unable to prevent the increase in glucose uptake upon piericidin-
A treatment. Of note, the antioxidants Trolox and Tempol only
partially diminished piericidin-A-induced HEt oxidation, leaving
open the possibility that the remaining ROS increase might still
suffice to activate AMPK and/or Glut1. Alternatively, AMPK-
independent signaling might be involved, although this is less likely
given the fact that AMPK knockdown completely prevented the
piericidin-A-induced stimulation of glucose uptake.
The mechanism by which AMPK stimulates Glut1-mediated
glucose uptake under conditions of metabolic stress has been
previously studied (Abbud et al., 2000; Barnes et al., 2002; Jing
et al., 2008). Co-immunoprecipitation studies reveal that pAMPK
does not bind to Glut1 under metabolic stress conditions (Jing and
Ismail-Beigi, 2007), suggesting that Glut1 is not directly
phosphorylated by AMPK. We observed that NADH levels were
increased in piericidin-A- and antimycin-A-treated cells, which is
probably due to the combined effects of decreased OXPHOS-
mediated NADH oxidation and increased glycolysis-mediated
NADH production. However, NAD+ levels were not reduced and
even appeared increased in inhibitor-treated cells. This might
suggest that acute mitochondrial inhibition stimulates de novo
synthesis of NAD+. Interestingly, the inhibitor-induced increase
in NADH and NAD+ was prevented by AMPK knockdown.
Mitochondrial dysfunction and changes in AMPK activity have
previously been linked to alterations in NADH and NAD+ levels,
the latter of which acts as a co-factor for sirtuin proteins (Forkink
et al., 2015a; Karamanlidis et al., 2013). Sirtuins are protein
deacetylases involved in cell cycle regulation, genomic stability
and energy metabolism (Choudhary et al., 2009, 2014). In contrast
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to other sirtuins, Sirt2 localizes predominantly in the cytosol
(North et al., 2003; Rauh et al., 2013). This suggests that Sirt2
might link AMPK phosphorylation to Glut1 activation.
Supporting this hypothesis, Sirt2 inhibition partially prevented
the piericidin-A- and antimycin-A-induced increase in glucose
uptake. However, we also observed that Sirt2 inhibition stimulated
glucose uptake under the vehicle-treated condition. This suggests
that Sirt2 might prevent excessive glucose uptake under normal
conditions, whereas it mediates stimulation of glucose uptake
during metabolic stress. In the nucleus, Sirt1 deacetylates LKB1,
leading to AMPK activation (Hou et al., 2008; Lan et al., 2008).
However, we observed that Sirt2 inhibition did not diminish
piericidin-A- and antimycin-A-induced AMPK phosphorylation,
suggesting that Sirt2 operates downstream of AMPK. A large
number of glycolytic enzymes can be acetylated, and reversible
acetylation is believed to fine-tune metabolic adaptation and
insulin signaling in muscle (LaBarge et al., 2015; Philp et al.,
2014). We here observed that the Glut1 acetylation status was
similar under basal and OXPHOS-inhibited conditions,
suggesting that Glut1 is not directly modulated by acetylation
and/or is not a direct target of Sirt2.
A potential downstream target of Sirt2 is Akt, which is involved
in insulin signaling and promotes a glycolytic phenotype in various
cell types (Elstrom et al., 2004; Higaki et al., 2008; Ramakrishnan
et al., 2014). Acetylation of Akt at residue Lys20 prevents
plasma membrane localization and activation of Akt by
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phosphatidylinositol 3-kinase (PI3K) (Sundaresan et al., 2011),
whereas deacetylation of Akt by Sirt2 is reported to promote its
activity (Chen et al., 2013; Dan et al., 2012). It has been previously
suggested that phosphorylation of Thr101 on Sirt2 by AMPK is
required for an Akt–Sirt2 interaction and subsequent activation by
PI3K upon insulin signaling (Ramakrishnan et al., 2014). However,
using the Akt inhibitor SC-66, we were unable to demonstrate the
above Akt involvement in our model system. In contrast, inhibition
of mTOR–RAPTOR greatly reduced the piericidin-A- and
antimycin-A-induced stimulation of glucose uptake. This is
compatible with the reduced glycolytic flux observed in
rapamycin-treated NDUFS4−/− mice with an isolated complex-I
deficiency (Johnson et al., 2013).
Taken together, our results suggest that the activity of LKB1,
AMPK, Sirt2 and mTOR–RAPTOR is required for the stimulation
of cellular glucose uptake induced by mitochondrial dysfunction.
We propose a mechanism (Fig. 7) in which acute inhibition of
complex I or complex III (transiently) increases AMP levels and
decreases ATP levels. These changes inhibit AMPK
dephosphorylation and stimulate LKB1-dependent AMPK
activation. Activated AMPK phosphorylates Sirt2, which leads to
activation of mTOR–RAPTOR and of Glut1 through an unknown
but possible Akt-independent mechanism.
MATERIALS AND METHODS
Chemicals
Sodium iodoacetic acid (IAA), antimycin A, AICAR, 2-cyano-3-[5-(2,5-
dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide (AGK2), trichostatin
A (TSA) and 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (4-hydroxy-
TEMPO or ‘Tempol’) were obtained from Sigma-Aldrich (Zwijndrecht, The
Netherlands). Piericidin A was obtained from Enzo Life Sciences
(Raamsdonksveer, The Netherlands). 6-[4-[2-(1-Piperidinyl)ethoxy]
phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine (Dorsomorphin or
Compound C) was obtained from Calbiochem (Billerica, MA). 6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) was
obtained from Fluka (Buchs, Switzerland). 2-morpholino-6-(thianthren-1-
yl)-4H-pyran-4-one (KU55933) was obtained from Abcam (Cambridge,
UK). Rapamycin was obtained from LC Laboratories (Woburn, MA).
Cell culture
C2C12 myoblasts were obtained from American Type Culture Collection
(Wesel, Germany) and cultured at 37°C (95% air, 5% CO2) in Dulbecco’s
modified eagle’s medium (DMEM-32430; Life Technologies Invitrogen,
Bleiswijk, The Netherlands), supplemented with 10% (v/v) fetal bovine
serum (FBS) (10270-106; Life Technologies Invitrogen). For glucose
measurements, myoblasts were seeded onto Fluorodishes® (#FD35-100;
World Precision Instruments, Sarasota, FL) at a density of 40,000 cells/dish.
Transfection
One day after seeding, C2C12 cells were at 40% confluence. DNA (1 µg) was
mixed with 6 µl of Lipofectamine (Life Technologies Invitrogen) in 0.5 ml
FBS-free DMEM. Following a 20-min incubation at room temperature, the
transfection mix was added to the cells in FBS-free DMEM. After 6 h, this
medium was replaced by DMEM containing 10% FBS. The glucose sensor
FLII12Pglu-700µδ6 (FLII) (Addgene Plasmid #17866) (Takanaga et al.,
2008) was created in the laboratory ofDrWolf Frommer (Department of Plant
Biology, Carnegie Institution for Science, CA).
Single-cell glucose uptake measurements
These experiments were performed as described in detail previously
(Liemburg-Apers et al., 2015a). Briefly, cells were washed and incubated
for 3 min in HEPES-Tris buffer (adjusted to pH 7.4 with Tris-HCl)
containing 4.2 mM KCl, 132 mM NaCl, 10 mM HEPES, 1.2 mM MgCl2
and 1 mM CaCl2. Next, cells were placed on an inverted microscope
(Axiovert 200 M, Carl Zeiss BV, Sliedrecht, The Netherlands). FLII was
excited at 430 nm (CFP) for 300 ms, CFP fluorescence was detected using a
455DRLP dichroic mirror (Omega Optical, Brattleboro, VT) and a
480AF30 emission filter (Omega). Citrine emission (citrineFRET) was
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Fig. 7. Proposed mechanism by which mitoenergetic
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measured using a 430-nm excitation light (for 200 ms), and emission was
detected using the 455DRLP dichroic mirror and a 535AF26 emission filter
(Omega). Time-lapse recordings were performed using an acquisition
interval of 2.5 s. Microscopy images were stored in native Metafluor format
(Universal Imaging Corporation, Downingtown, PA) and analyzed off-line
using Image Pro Plus 6.1 software (Media Cybernetics, Rockville).
Individual images were background-corrected for the individual
wavelengths by subtracting the average intensity in an extracellular region
of interest. Next, cell-derived fluorescence signals were quantified using
cytosolic circular regions of interest. CitrineFRET:CFP emission ratios were
converted to [GLC]c using a previously generated in situ calibration curve
(Liemburg-Apers et al., 2015a).
QPCR analysis
This was performed as described previously (Liemburg-Apers et al., 2015a).
The primer sequences (forward and reverse) were: Glut1, 5′-TGCAGTT-
CGGCTATAACACTG-3′ and 5′-GGTGGTTCCATGTTTGATTG-3′; Gl-
ut2, 5′-TGTGATCAATGCACCTCAAG-3′ and 5′-TCATAGTT-
AATGGCAGCTTTCC-3′; Glut3, 5′-ACTCTTTGTCAACCGCTTTG-3′
and 5′-ATCTTGGCGAATCC-CATAAG-3′; Glut4, 5′-CTTGGCTCCCT-
TCAGTTTG-3′ and 5′-CACGTTGCATTGTAGCTCTG-3′; and actin, 5′-
CTAAGGCCAACCGTGAAAAG-3′ and 5′-TACGACCAGAGGCATA-
CAGG-3′.
Preparation of cell lysates
Cells were scraped and centrifuged at 600 g for 5 min at 4°C. Cell pellets were
lysed in RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 50 mM NaCl,
5 mM EDTA, 1% (w/v) deoxycholate, 1% (w/v) Triton X-100, 10 mM
Na4P2O7, 50 mM NaF, 0.1 mg/ml DNase and 1× protease inhibitor cocktail.
After 30 min of incubation under gentle rotation at 4°C, cell suspensions were
centrifuged at 15,000 g for 10 min at 4°C, and supernatants were used for
protein concentration determination by measuring the absorption at 280 nm
using a Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific,
Waltham, MA).
Western blot analysis
Proteins were denatured (70°C; 10 min) in sample buffer containing
250 mM Tris-HCl (pH 6.8), 160 mM dithiothreitol, 2% (w/v) SDS, 12%
(v/v) glycerol and 0.03% (w/v) Bromophenol Blue. Proteins (30 µg/lane)
were separated on 10% SDS-PAGE gels and transferred to polyvinylidene
difluoride (PVDF) or nitrocellulose membranes (Novex, Thermo Fisher
Scientific). Membranes were blocked with Odyssey blocking buffer
(Li-Cor, Lincoln, NE, USA) diluted 1:1 in PBS (v/v) and incubated with
primary antibodies. Polyclonal anti-Glut1 (1:500; #07-1401), monoclonal
anti-LKB1 (1:1000; #05-832) and polyclonal anti-pLKB1 (Ser431)
(1:1000; #09-495) antibodies were obtained from Millipore (Billerica,
MA). Polyclonal anti-AMPK (1:1000; #2532L), monoclonal anti-pAMPK
(Thr172) (1:1000; #2535L) and anti-pACC (Ser79) (1:1000; #3661S)
antibodies were obtained from Cell Signaling (Bioke, Leiden, The
Netherlands). Monoclonal anti-β-Actin (1:10.000; #A5441) antibody was
obtained from Sigma. For detection, IRDye 680RD-conjugated goat anti-
mouse IgG (1:10.000) and IRDye 800CW-conjugated goat anti-rabbit IgG
(1:10.000) (Li-Cor, Lincoln, NE) secondary antibodies were used.
Membranes were scanned, and band intensities were quantified with
Image Studio Lite software (Li-Cor; version 4.0).
Immunocytochemistry of Glut1
After treatments, cells were fixed using 4% (v/v) formaldehyde in PBS for
15 min. Immunocytochemistry was performed as described in detail
previously (Grefte et al., 2015). Briefly, cells were permeabilized in 0.5%
(v/v) Triton X-100 in PBS for 20 min. After washing, cells were blocked
in blocking buffer containing 2% (w/v) bovine serum albumin (BSA), 2%
(v/v) normal goat serum (NGS), 0.1% (v/v) Triton X-100, 0.05% (v/v)
Tween-20 and 100 mM glycine in PBS for 30 min. Cells were incubated
with mouse anti-Glut1 (1:100; 07-1404, Millipore) antibody in blocking
buffer without glycine for 1 h. Glut1 was detected with Alexa-Fluor-488-
labeled goat anti-rabbit antibody (1:200; Molecular Probes, Leiden, The
Netherlands). Cells were sealed using Vectashield mounting medium
containing 4′,6-diamidino-2-phenylindole (DAPI), which stains all nuclei
(Vector Laboratories, Burlingame, CA). Images were taken on an Olympus
FV1000 confocal laser-scanning microscope.
Cell surface protein biotinylation
Biotinylation was performed using the Pierce cell surface protein isolation
kit (89881; Thermo Fisher Scientific) according to the manufacturer’s
protocol. For each condition, two confluent T175 culture flasks were used.
After treatment, cells were incubated with Sulfo-NHS-SS-biotin, and cell
membrane integrity was assessed visually and proven to be intact.
Biotinylated proteins were purified using NeutrAvidin agarose resin and
loaded onto a gel and analyzed by western blotting with an anti-Glut1
antibody (see above).
Gene knockdown
AMPK knockdown was performed by transfecting 75,000 cells with 60 ng
of siRNA directed against AMPK α1 and AMPK α2 subunits (sc-45313) or
scramble siRNA (sc-37007) (Santa Cruz Bioconnect Life Sciences,
Huissen, The Netherlands). LKB1 knockdown was performed by
transfecting 75,000 cells with 100 nM siRNA directed against LKB1
(s74499) or a scrambled siRNA (Silencer select negative control No. 1)
(Life Technologies Invitrogen). Transfection with siRNA was performed
using the Neon® Transfection System (Life Technologies Invitrogen)
according to manufacturer’s protocol for C2C12 myoblasts. One day after
siRNA addition, cells were transfected with FLII using Lipofectamine (see
the above section on transfection). Two days after siRNA addition, cells
were used for experiments.
NAD+ and NADH measurements
Per sample, 50,000 cells were seeded in a 6-well plate and used the next
day for measurements. For AMPK-knockdown experiments, cells were
transfected with siRNA, seeded in 6-well plates and used for measurement
2 days later. Cells were treated for 30 min with mitochondrial inhibitors, after
which they were scraped, and NAD+ and NADH were quantified using the
EnzyFluo™ NAD+:NADH assay kit (EFND-100, BioAssay Systems,
Hayward, CA) according to the manufacturer’s protocol. Upon the addition
of reagent, the optical density (OD) at 560 nm was measured using a 2-min
interval on the Synergy 2 multi-mode reader (Biotek, Abcoude, The
Netherlands). The ΔOD (10 min) values were normalized to those for the
vehicle-treated condition for each experiment.
HEt oxidation
The levels of HEt-oxidizing ROS were determined as described in detail
previously (Forkink et al., 2015b;Grefte et al., 2015). Cellswere pretreated for
30 min with mitochondrial inhibitors followed by an 18-min incubation in the
absence of glucose, of which the last 15 min were in the presence of IAA and
the last 5 min in the presence of 10 μM HEt (Life Technologies Invitrogen).
Next, the cells werewashed with HEPES-Tris buffer, and Fluorodishes® were
mounted in an incubation chamber and placed on the stage of an inverted
microscope (Carl Zeiss, see above). Cells were excited at 490 nm for 100 ms,
and fluorescence emission was detected by a 565ALP emission filter
(Omega). Quantitative analyses were performed using Metamorph 6.0
software (Universal Imaging Corporation). The mean fluorescence intensity
in a mitochondria-dense and nuclear region was determined for at least ten
different microscopic fields and corrected for background intensity using an
extracellular region of identical size. For each experiment, two dishes and a
minimum of 30 cells were analyzed per tested condition.
Immunoprecipitation
For protein acetylation analysis, lysate preparation and immunoprecipitation
was performed in the presence of nicotinamide (NAM; 10 mM) and TSA
(1 µM). Immunoprecipitation of acetylated proteins was performed by
incubating 1 g of protein cell lysate with 5 µg of mouse anti-acetyl-lysine
antibody (clone 4G12, Millipore) overnight at 4°C. On the following day,
100 µl of Dynabeads® Protein G (Novex, Thermo Fisher Scientific) were
added and incubated for 2 h at 4°C. The beads were washed three times with
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PBS, and proteins were eluted in 30 µl of 4× sample buffer at 70°C for
10 min and analyzed by western blotting. Acetylated Glut1 was quantified
by correcting the Glut1 signal for the loading control of the anti-acetyl-
lysine antibody heavy chain. Immunoprecipitation of Glut1 was performed
by covalently cross-linking rabbit anti-Glut1 (ab32551, Abcam, Cambridge,
UK) antibody to Dynabeads® Protein G. After a 10 min incubation under
gentle rotation of 50 µl Dynabeads® Protein G with 5 µg anti-Glut antibody,
beads were washed three times in conjugation buffer containing 20 mM
sodium phosphate, 0.15 M NaCl (pH 7–9) and incubated for 30 min under
gentle rotation at room temperature in conjugation buffer containing 5 mM
of the amine-to-amine crosslinker bis(sulfosuccinimidyl)suberate (BS3;
Thermo Fisher Scientific). Cross-linking was quenched by adding 16 mM
Tris (pH 7.5) and incubating for 15 min under gentle rotation at room
temperature. Next, beads were washed three times in PBST (PBS+0.01%
Tween) and gently rotated with 2 g of protein cell lysate for 15 min at room
temperature. Beads were washed three times with PBS, and proteins were
eluted in 30 µl of 4× sample buffer at 70°C for 10 min and analyzed by
western blotting. The amount of acetylated Glut1 was quantified by
normalizing the acetylation signal to the Glut1 signal.
Statistical analysis
Average values are presented as mean±s.e.m. Curve fitting and statistical
analysis were performed using Origin Pro 6.1 (OriginLab Corp.,
Northampton, USA) and GraphPad Prism 5 (Graphpad Software, La
Jolla, CA). Unless stated otherwise, statistical significance relative to the
indicated condition was determined using a Kruskal–Wallis test (followed
by a Dunn’s post-hoc test) or a two-way ANOVA (followed by Bonferroni
post-hoc test); ***P<0.001, **P<0.01 and *P<0.05.
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